US Food and Drug Administration awards Critical Path Institute 3 grants, 1 contract

The US Food and Drug Administration (FDA) has awarded Critical Path Institute (C-Path) three grants to develop data standards, as well as a contract to continue its research into drug-induced kidney injury. With these awards, the FDA continues to support C‑Path’s efforts to advance translational research toward accelerating drug development and regulatory review.Continue reading

To Treat the Heart, Neurotechnology Aims to Balance the Brain

Brain State Technologies (Scottsdale, Arizona) has  announced that use of their allostatic neurotechnology was associated with positive effects for the cardiovascular system and reduction of inflammation, in individuals with diverse health conditions. The findings are being presented at the Council on Hypertension of the American Heart Association, meeting in Orlando, Florida from September 14-17.Continue reading

TB-REFLECT: A COLLABORATIVE EFFORT TO ENHANCE TB CLINICAL RESEARCH

TUCSON, October 25, 2016 – The Critical Path Institute’s (C-Path) Critical Path to TB Drug Regimens (CPTR) initiative and the Global TB Programme of the World Health Organization (WHO) have partnered with researchers from the University of California, San Francisco (UCSF), to develop leading-edge quantitative analyses of data from the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS)database. This collaboration, called TB-ReFLECT, will extract from these analyses key lessons from the TB-PACTS platform, and then package such lessons as tools for future TB trial design.Continue reading